Claims
- 1. A method of treating glaucoma or ocular hypertension in a patient, which comprises administering to the patient a pharmaceutically effective amount of a compound of formula I:
- 2. The method of claim 1, wherein the compound is administered topically.
- 3. The method of claim 2, wherein the compound is administered as a solution, suspension or emulsion.
- 4. The method of claim 1,wherein for the compound of formula I:
R1═CO2R, where R═H; or CO2R=ophthalmically acceptable ester moiety, where R=alkyl; n=0; - - - =a single bond between carbons 5 and 6, a cis double bond between carbons 4 and 5, and a single or trans double bond between carbons 13 and 14; R2═R3═H; D=fluorine in the alpha (α) configuration, and D1═H in the beta (β) configuration; X═CH2O or CH2CH2; and Y=phenyl, optionally substituted with halo or trihalomethyl.
- 5. The method of claim 2, wherein the concentration of the compound is between about 0.00003 to about 0.5 weight percent.
- 6. The method of claim 5, wherein the concentration of the compound is between about 0.0005 to about 0.03 weight percent.
- 7. The method of claim 6, wherein the concentration of the compound is between about 0.001 to about 0.01 weight percent.
- 8. The method of claim 5, wherein the compound is:
- 9. A compound of formula I:
- 10. The compound of claim 9, wherein:
R1═CO2R, where R═H; or CO2R=pharmaceutically acceptable ester moiety; n═0; - - - =a single bond between carbons 5 and 6, a cis double bond between carbons 4 and 5, and a single or trans double bond between carbons 13 and 14; R2═R3═H; D=fluorine in the alpha (α) configuration, and D1═H in the beta (β) configuration; X═CH2O or CH2CH2; and Y=phenyl, optionally substituted with halo or trihalomethyl.
- 11. The compound of claim 10, wherein the pharmaceutically acceptable ester moiety is a carboxylic acid alkyl ester moiety.
- 12. The compound of claim 11, having the formula:
- 13. A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension, comprising a compound of formula I:
- 14. The composition of claim 13, wherein:
R1═CO2R, where R═H; or CO2R=ophthalmically acceptable ester moiety; n=0; - - - =a single bond between carbons 5 and 6, a cis double bond between carbons 4 and 5, and a single or trans double bond between carbons 13 and 14; R2═R3═H; D=fluorine in the alpha (α) configuration, and D1═H in the beta (β) configuration; X═CH2O or CH2CH2; and Y=phenyl, optionally substituted with halo or trihalomethyl.
- 15. The composition of claim 14, wherein the ophthalmically acceptable ester moiety is a lower alkyl carboxylic acid alkyl ester moiety.
- 16. The composition of claim 15, wherein the compound is:
RELATED APPLICATION
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/284432 filed Apr. 12, 1999, which is a national application under 35 USC §371 of PCT Application Serial No. PCT/US97/20671 filed Nov. 7, 1997, which draws priority from U.S. Provisional Application Serial No. 60/030519 filed Nov. 12, 1996, now abandoned.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60030519 |
Nov 1996 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09284432 |
Jun 1999 |
US |
Child |
10100399 |
Mar 2002 |
US |